Haematological Oncology
Secura Bio Limited is active in blood cancer research, with a particular focus on nodal T-cell lymphoma and disease that has relapsed or become refractory after prior treatment.
- T-cell lymphoma
- Relapsed/refractory disease
- Nodal lymphoma
The sponsor’s current clinical activity centers on a rare lymphoid malignancy affecting patients with limited treatment options.
T Follicular Helper (TFH) Phenotype Malignancies
Its research interest extends to T follicular helper (TFH) phenotype disease, reflecting a focus on biologically defined subtypes within T-cell lymphoma.
- TFH phenotype
- Biomarker-defined lymphoma
- Subtype-specific oncology
This area highlights attention to molecularly and immunologically distinct forms of lymphoma.
Targeted Therapy in Lymphoma
The sponsor is involved in clinical research evaluating targeted anti-cancer therapy in comparison with established chemotherapy options for lymphoma.
- Duvelisib
- PI3K pathway inhibition
- Comparator chemotherapy
Its therapeutic interest lies in treatment strategies for patients with aggressive hematologic malignancies.
Refractory Cancer Treatment Options
Secura Bio Limited also focuses on salvage treatment settings, where disease persists or returns after earlier lines of therapy.
- Refractory lymphoma
- Post-treatment relapse
- Unmet need in oncology
This clinical area addresses patients who require alternative approaches after standard regimens such as gemcitabine or bendamustine.
